Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Pivotal Study Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Study Active, not recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

Sep 18, 2023

Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing

Sep 11, 2023

Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

Sep 5, 2023

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

Aug 14, 2023

Cellectar Provides a Research and Development Program Summary

Jun 12, 2023

UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

May 4, 2023

Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

May 4, 2023

Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update

Mar 9, 2023

Cellectar to Participate at Upcoming Banking Conferences

Mar 8, 2023

Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient

Feb 28, 2023
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...31
© 2023 Cellectar Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Q&A